Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

684
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
684
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

740
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
740
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.0K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.0K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.5K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.5K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

2.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time trends in strategies for postoperative Crohn's disease management and long-term surgical recurrence: ENEIDA registry data.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Characterization of the stages of chronic liver disease based on plasma proteins involved in systemic inflammation.

Revista espanola de enfermedades digestivas·2026
Same author

Clinical features and therapeutic requirements of perianal disease in adult patients with ulcerative colitis: the PERICO study of the ENEIDA registry.

Inflammatory bowel diseases·2026
Same author

Real-World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry.

Alimentary pharmacology & therapeutics·2026
Same author

The Telemonitorización de la Enfermedad de Crohn y Colitis Ulcerosa (Telemonitoring of Crohn's Disease and Ulcerative Colitis)-Based Telemonitoring Platform for Inflammatory Bowel Disease Is Cost-Effective: A Multicenter Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa Trial.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Influence of vedolizumab on extraintestinal manifestations in inflammatory bowel disease: a nationwide multicenter study of the GETECCU ENEIDA Registry.

Journal of Crohn's & colitis·2026

Related Experiment Video

Updated: Apr 20, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.9K

[Mesalazine old and new].

Míriam Mañosa1, Eugeni Domènech2

  • 1Unidad de Enfermedades Inflamatorias Intestinales, Servicio de Aparato Digestivo, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, España.

Gastroenterologia Y Hepatologia
|December 3, 2014
PubMed
Summary

Aminosalicylates (5-ASA) are effective for ulcerative colitis, but oral delivery is limited. Novel rectal formulations, including a multi-matrix system, may enhance therapeutic outcomes.

Keywords:
AminosalicilatosAminosalycylatesColitis ulcerosaMesalazinaMesalazineMulti-matrixMultimatrixUlcerative colitis

More Related Videos

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

2.1K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K

Related Experiment Videos

Last Updated: Apr 20, 2026

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.9K
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
04:47

Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice

Published on: October 27, 2023

2.1K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.6K

Area of Science:

  • Gastroenterology
  • Pharmacology
  • Drug Delivery Systems

Background:

  • Aminosalicylates (5-ASA) are primary treatments for ulcerative colitis (UC) and remission maintenance.
  • Oral 5-ASA efficacy is often compromised by pharmacological limitations.
  • Rectal administration of 5-ASA offers improved therapeutic efficiency.

Purpose of the Study:

  • To review the efficacy of existing galenic preparations of 5-ASA.
  • To discuss the potential benefits of novel multi-matrix delivery systems for 5-ASA.

Main Methods:

  • Literature review of placebo-controlled trials on 5-ASA efficacy.
  • Analysis of data on rectal administration of 5-ASA formulations.
  • Evaluation of novel galenic forms with multi-matrix coating.

Main Results:

  • Aminosalicylates (5-ASA) demonstrate proven efficacy in placebo-controlled trials for UC.
  • Rectal administration enhances the therapeutic effect of 5-ASA compared to oral routes.
  • Novel multi-matrix delivery systems show potential for optimizing 5-ASA efficacy.

Conclusions:

  • Rectal administration is key to optimizing 5-ASA therapy for ulcerative colitis.
  • New galenic formulations, particularly those with multi-matrix systems, warrant further investigation for improved UC management.